Emvena Therapeutics, a biotechnology startup developing mRNA medicines for maternal and fetal conditions, has received investment from the Penn-BioNTech Innovative Therapeutics Seed Fund (PxB Fund). The company is the first startup launched and financed by the fund, which supports the development of promising research from the University of Pennsylvania.
Founded in 2026 Philadelphia-based Emvena is developing treatments designed to deliver mRNA directly to the placenta. Its lead program focuses on preeclampsia, a serious pregnancy complication that affects an estimated 2% to 8% of pregnancies worldwide.
Preeclampsia is a major cause of maternal and infant illness and death. There are currently no approved treatments that address the underlying disease. Treatment options are limited to managing symptoms and, in severe cases, delivering the baby prematurely.
Developing Placenta-Targeted mRNA Medicines
Emvena is advancing technology developed in the laboratory of Michael J. Mitchell, PhD, the Hibbert Professor of Bioengineering at the University of Pennsylvania’s School of Engineering and Applied Science.
Research published in Nature demonstrated that a novel lipid nanoparticle (LNP) could deliver mRNA to the placenta more effectively than conventional LNPs. The Mitchell Lab also found that delivering mRNA encoding vascular endothelial growth factor (VEGF), a protein involved in blood vessel growth, reduced disease severity in mouse models of preeclampsia.
Building on this research, Emvena is developing placenta-targeted mRNA medicines aimed at treating preeclampsia and other maternal and fetal conditions with limited treatment options.
First Company Backed by the PxB Fund
The Penn-BioNTech Innovative Therapeutics Seed Fund supports the translation of promising University of Pennsylvania research into potential therapies that advance human health.
Emvena is the fund’s first company investment and launch. The investment will support the development of its mRNA platform and lead program, which targets a significant unmet medical need in maternal health.
The company’s approach is based on the potential to deliver treatments directly to the placenta, with the goal of addressing serious pregnancy-related conditions.
